DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema

Information source: Hospital Juarez de Mexico
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetic Retinopathy; Diabetic Macular Edema

Intervention: Dorzolamide hydrochloride (2%) (Drug); Placebo Sodium hyaluronate 4mg (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Hospital Juarez de Mexico

Official(s) and/or principal investigator(s):
Virgilio Lima Gomez, MD, PhD, Principal Investigator, Affiliation: Hospital Juárez de México
Dulce Mi Razo-Blanco Hernandez, MD, PhD, Study Chair, Affiliation: Hospital Juarez de Mexico
Surisadai Serafín Solis, Study Chair, Affiliation: Instituto Politecnico Nacional

Overall contact:
Virgilio Lima Gómez, MD, PhD, Phone: 015255477560, Ext: 7503, Email: vlimag@eninfinitum.com


Photocoagulation is the standard treatment in the focal EMCS, disrupts vascular leakage and allows the pigment epithelium remove the intraretinal fluid is effective in reducing the incidence of visual loss but can reduce contrast sensitivity and retinal sensitivity, the characteristics of the function can be reduced such as setting (location and stability) are relevant to the quality of the patient's vision parameters, reading comprehension, especially the ability, duration of diabetic macular edema, could have a significant impact on survival and / or the functional reserve of the macular cells subjected to mechanical and toxic stress-induced edema. It seems that in the treatment of patients with EMCS, photoreceptor damage occurs as a recent phenomenon, and can precede neurodegeneration retinal photoreceptor loss, whereby visual function can be decreased. An adjunctive treatment as Dorzolamide facilitating effect helping resorption of intraretinal fluid through EPR and reduce adverse events that is the loss of contrast sensitivity and retinal sensitivity, response time of photocoagulation treatment could be reduced to the patient, because the rate of resorption of intraretinal fluid is facilitated and thus the duration of the response, also could reduce damage to vision caused by the inadequacies of the photoreceptors during the evolution of macular edema avoiding moderate visual loss, there by increasing the quality of life in terms of improving the quality of vision in diabetic patients. In addition to obtaining a specific adjuvant treatment with photocoagulation is helpful for focal edema in diabetic and a new level using dorzolamide in retina Dorzolamide as adjunctive therapy after focal photocoagulation is more effective than placebo in improving visual function in patients with diabetic macular edema

Clinical Details

Official title: Efficacy of Dorzolamide as an Adjuvant to Improve Visual Function After Focal Photocoagulation Treatment in Diabetic Patients With Clinically Significant Macular Edema

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: efficiency in visual function with dorzolamide after photocoagulation

Detailed description: Patients referred to ophthalmology for developing type 2 diabetes subspecialist ophthalmologist evaluate the macula them by biomicroscopy, pupillary dilation, to detect clinically significant macular edema. EMCS diagnosis is made according to ETDRS criteria, and patients who were requested to submit fluorescein angiography. Patients presenting with focal leakage on angiography were scheduled focal photocoagulation; day focal photocoagulation is measured before the procedure Measurement of visual acuity, visual acuity, refraction Measuring contrast sensitivity Measurement of retinal sensitivity Measurement of Optical Coherence Tomography ophthalmoscopic review Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS (1-50 number of shots, shot diameter of 100 microns and 120-180 mW power) and the patient was re-evaluated at 4 weeks, which will repeat the testing day photocoagulation. The patient what the research project will be discussed, will be invited to participate, will be read and informed consent was explained, questions and concerns will be clarified during the study, and patients who agree to enter the study will be assigned so random treatment. Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye is placed, the drug provided will be needed for 4 weeks, plus a control sheet dose delivery will be provided and shall be referenced again in April weeks later for evaluation: After 4 weeks of topical treatment, evaluation from 8: 00 to 11 pm will be the same from the first date


Minimum age: 40 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- • Patients 40 to 70 years with diabetic retinopathy indistinct gender

- Clinically significant macular edema

- Focal Filtration in fluorescein angiography

- Means optical transparent

- Haemoglobin less than 7% (170)

- Best-corrected visual acuity ≥ 20/200

- Signed Informed Consent

Exclusion Criteria:

- • Presence of other retinal or optic nerve diseases

- Presence of any other maculopathy

- Patient diagnosed with allergy to sulfa

- Patient with previous eye surgery four months

- Patients with prior application of focal photocoagulation

- Patients who use contact lenses 2 days before the application of


- Presence of external eye disease, infection, inflammation at the time of


- The presence of corneal disease present

- Refractive errors higher than 6. 00 D (sphere) -3. 00 D (cylinder)

- Study macular Fluorangiography Ischemia

- Thickness of the central field> 300 microns

Locations and Contacts

Virgilio Lima Gómez, MD, PhD, Phone: 015255477560, Ext: 7503, Email: vlimag@eninfinitum.com

Hospital Juarez de Mexico, Mexico City 07760, Mexico; Recruiting
VIRGILIO LIMA GOMEZ, MD, PhD, Phone: 015255477560, Ext: 7503, Email: vlimag@eninfinitum.com
DULCE MI RAZO-BLANCO HERNANDEZ, MD, PhD, Phone: 015255477560, Ext: 7503, Email: razoblanco.dulce@gmail.com
Virgilio Lima Gomez, Md, PhD, Principal Investigator
Surisadai Serafín Solís, Sub-Investigator
Additional Information

Starting date: January 2014
Last updated: March 18, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017